Pardes Biosciences, Inc. (PRDS): Price and Financial Metrics

Pardes Biosciences, Inc. (PRDS): $2.16

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

Add PRDS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#160 of 374

in industry

PRDS Price/Volume Stats

Current price $2.16 52-week high $3.93
Prev. close $2.16 52-week low $0.75
Day low $2.13 Volume 2,378,900
Day high $2.20 Avg. volume 359,530
50-day MA $2.03 Dividend yield N/A
200-day MA $1.70 Market Cap 133.95M

PRDS Stock Price Chart Interactive Chart >


Pardes Biosciences, Inc. (PRDS) Company Bio


Pardes Biosciences, Inc., a pre-clinical stage biotechnology company, engages in developing oral direct acting antivirals. Its antivirals target viral main cysteine protease, an essential viral protein required for coronaviruses to replicate. Pardes Biosciences, Inc. was incorporated in 2020 and is based in Carlsbad, California.


PRDS Latest News Stream


Event/Time News Detail
Loading, please wait...

PRDS Latest Social Stream


Loading social stream, please wait...

View Full PRDS Social Stream

Latest PRDS News From Around the Web

Below are the latest news stories about PARDES BIOSCIENCES INC that investors may wish to consider to help them evaluate PRDS as an investment opportunity.

Pardes Biosciences Announces Closing of Tender Offer

CARLSBAD, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) (Pardes or the Company) today announced that MediPacific, Inc. (MediPacific), an affiliate of Foresite Capital, through its wholly owned subsidiary MediPacific Sub, Inc. (Merger Sub), has successfully completed the previously announced tender offer to acquire all of Pardes’ outstanding shares of common stock for a per share price of (i) $2.13 in cash (the Cash Amount), plus (ii) a non-tradeable contingent

Yahoo | August 31, 2023

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

LARKSPUR, Calif., August 28, 2023--As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (Nasdaq: PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share in cash, plus a non-tradeable contingent value right (the "CVR") associa

Yahoo | August 28, 2023

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

LARKSPUR, Calif., August 17, 2023--As previously announced, on July 16, 2023, MediPacific Sub, Inc. ("Purchaser") and MediPacific, Inc. ("Parent"), affiliates of Foresite Capital, entered into a definitive agreement and plan of merger (the "Merger Agreement") with Pardes Biosciences, Inc. (Nasdaq: PRDS) ("Pardes") whereby Purchaser agreed to acquire, subject to the terms of the Merger Agreement, Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more

Yahoo | August 17, 2023

Pardes Biosciences Enters into Agreement to be Acquired by MediPacific, Inc. for between $2.02 and $2.19 in Cash per Share Plus Contingent Value Rights

CARLSBAD, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS) today announced that it has entered into a definitive merger agreement whereby MediPacific, Inc. (Purchaser) will acquire Pardes for a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share, with the final price per share being based on the amount of the Company’s net cash at closing, plus a non-tradeable contingent value right (the CVR) associated wi

Yahoo | July 17, 2023

Pardes Biosciences Reports First Quarter 2023 Financial Results

CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023. “As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternatives to maximize shareholder value that may potentially result in changes to our business strategy,” said Thomas G. Wiggans, Chief Executive Officer and Chair of Pardes Biosciences. First Quarter 2023 Financial Results Pard

Yahoo | May 5, 2023

Read More 'PRDS' Stories Here

PRDS Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year 78.51%
3-year -78.34%
5-year N/A
YTD N/A
2023 0.00%
2022 -89.68%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!